table of content
Chapter 1 Industry Overview
1.1 Definition
1.2 Assumptions
1.3 Research Scope
1.4 Market Analysis by Regions
1.4.1 North America Market States and Outlook (2023-2030)
1.4.2 East Asia Market States and Outlook (2023-2030)
1.4.3 Europe Market States and Outlook (2023-2030)
1.4.4 South Asia Market States and Outlook (2023-2030)
1.4.5 Southeast Asia Market States and Outlook (2023-2030)
1.4.6 Middle East Market States and Outlook (2023-2030)
1.4.7 Africa Market States and Outlook (2023-2030)
1.4.8 Oceania Market States and Outlook (2023-2030)
1.4.9 South America Market States and Outlook (2023-2030)
1.5 Global Ankylosing Spondylitis Drug Market Size Analysis from 2023 to 2030
1.5.1 Global Ankylosing Spondylitis Drug Market Size Analysis from 2023 to 2030 by Consumption Volume
1.5.2 Global Ankylosing Spondylitis Drug Market Size Analysis from 2023 to 2030 by Value
1.5.3 Global Ankylosing Spondylitis Drug Price Trends Analysis from 2023 to 2030
1.6 COVID-19 Outbreak: Ankylosing Spondylitis Drug Industry Impact
Chapter 2 Global Ankylosing Spondylitis Drug Competition by Types, Applications, and Top Regions and Countries
2.1 Global Ankylosing Spondylitis Drug (Volume and Value) by Type
2.1.1 Global Ankylosing Spondylitis Drug Consumption and Market Share by Type (2017-2022)
2.1.2 Global Ankylosing Spondylitis Drug Revenue and Market Share by Type (2017-2022)
2.2 Global Ankylosing Spondylitis Drug (Volume and Value) by Application
2.2.1 Global Ankylosing Spondylitis Drug Consumption and Market Share by Application (2017-2022)
2.2.2 Global Ankylosing Spondylitis Drug Revenue and Market Share by Application (2017-2022)
2.3 Global Ankylosing Spondylitis Drug (Volume and Value) by Regions
2.3.1 Global Ankylosing Spondylitis Drug Consumption and Market Share by Regions (2017-2022)
2.3.2 Global Ankylosing Spondylitis Drug Revenue and Market Share by Regions (2017-2022)
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.1.1 2017-2022 Global Capacity, Production, Capacity Utilization Rate, Ex-Factory Price, Revenue, Cost, Gross and Gross Margin Analysis
3.1.2 2017-2022 Major Manufacturers Performance and Market Share
3.2 Regional Production Market Analysis
3.2.1 2017-2022 Regional Market Performance and Market Share
3.2.2 North America Market
3.2.3 East Asia Market
3.2.4 Europe Market
3.2.5 South Asia Market
3.2.6 Southeast Asia Market
3.2.7 Middle East Market
3.2.8 Africa Market
3.2.9 Oceania Market
3.2.10 South America Market
3.2.11 Rest of the World Market
Chapter 4 Global Ankylosing Spondylitis Drug Sales, Consumption, Export, Import by Regions (2017-2022)
4.1 Global Ankylosing Spondylitis Drug Consumption by Regions (2017-2022)
4.2 North America Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.3 East Asia Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.4 Europe Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.5 South Asia Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.6 Southeast Asia Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.7 Middle East Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.8 Africa Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.9 Oceania Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
4.10 South America Ankylosing Spondylitis Drug Sales, Consumption, Export, Import (2017-2022)
Chapter 5 North America Ankylosing Spondylitis Drug Market Analysis
5.1 North America Ankylosing Spondylitis Drug Consumption and Value Analysis
5.1.1 North America Ankylosing Spondylitis Drug Market Under COVID-19
5.2 North America Ankylosing Spondylitis Drug Consumption Volume by Types
5.3 North America Ankylosing Spondylitis Drug Consumption Structure by Application
5.4 North America Ankylosing Spondylitis Drug Consumption by Top Countries
5.4.1 United States Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
5.4.2 Canada Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
5.4.3 Mexico Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 6 East Asia Ankylosing Spondylitis Drug Market Analysis
6.1 East Asia Ankylosing Spondylitis Drug Consumption and Value Analysis
6.1.1 East Asia Ankylosing Spondylitis Drug Market Under COVID-19
6.2 East Asia Ankylosing Spondylitis Drug Consumption Volume by Types
6.3 East Asia Ankylosing Spondylitis Drug Consumption Structure by Application
6.4 East Asia Ankylosing Spondylitis Drug Consumption by Top Countries
6.4.1 China Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
6.4.2 Japan Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
6.4.3 South Korea Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 7 Europe Ankylosing Spondylitis Drug Market Analysis
7.1 Europe Ankylosing Spondylitis Drug Consumption and Value Analysis
7.1.1 Europe Ankylosing Spondylitis Drug Market Under COVID-19
7.2 Europe Ankylosing Spondylitis Drug Consumption Volume by Types
7.3 Europe Ankylosing Spondylitis Drug Consumption Structure by Application
7.4 Europe Ankylosing Spondylitis Drug Consumption by Top Countries
7.4.1 Germany Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.2 UK Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.3 France Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.4 Italy Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.5 Russia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.6 Spain Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.7 Netherlands Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.8 Switzerland Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
7.4.9 Poland Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 8 South Asia Ankylosing Spondylitis Drug Market Analysis
8.1 South Asia Ankylosing Spondylitis Drug Consumption and Value Analysis
8.1.1 South Asia Ankylosing Spondylitis Drug Market Under COVID-19
8.2 South Asia Ankylosing Spondylitis Drug Consumption Volume by Types
8.3 South Asia Ankylosing Spondylitis Drug Consumption Structure by Application
8.4 South Asia Ankylosing Spondylitis Drug Consumption by Top Countries
8.4.1 India Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
8.4.2 Pakistan Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
8.4.3 Bangladesh Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 9 Southeast Asia Ankylosing Spondylitis Drug Market Analysis
9.1 Southeast Asia Ankylosing Spondylitis Drug Consumption and Value Analysis
9.1.1 Southeast Asia Ankylosing Spondylitis Drug Market Under COVID-19
9.2 Southeast Asia Ankylosing Spondylitis Drug Consumption Volume by Types
9.3 Southeast Asia Ankylosing Spondylitis Drug Consumption Structure by Application
9.4 Southeast Asia Ankylosing Spondylitis Drug Consumption by Top Countries
9.4.1 Indonesia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.2 Thailand Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.3 Singapore Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.4 Malaysia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.5 Philippines Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.6 Vietnam Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
9.4.7 Myanmar Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 10 Middle East Ankylosing Spondylitis Drug Market Analysis
10.1 Middle East Ankylosing Spondylitis Drug Consumption and Value Analysis
10.1.1 Middle East Ankylosing Spondylitis Drug Market Under COVID-19
10.2 Middle East Ankylosing Spondylitis Drug Consumption Volume by Types
10.3 Middle East Ankylosing Spondylitis Drug Consumption Structure by Application
10.4 Middle East Ankylosing Spondylitis Drug Consumption by Top Countries
10.4.1 Turkey Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.2 Saudi Arabia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.3 Iran Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.4 United Arab Emirates Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.5 Israel Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.6 Iraq Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.7 Qatar Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.8 Kuwait Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
10.4.9 Oman Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 11 Africa Ankylosing Spondylitis Drug Market Analysis
11.1 Africa Ankylosing Spondylitis Drug Consumption and Value Analysis
11.1.1 Africa Ankylosing Spondylitis Drug Market Under COVID-19
11.2 Africa Ankylosing Spondylitis Drug Consumption Volume by Types
11.3 Africa Ankylosing Spondylitis Drug Consumption Structure by Application
11.4 Africa Ankylosing Spondylitis Drug Consumption by Top Countries
11.4.1 Nigeria Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
11.4.2 South Africa Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
11.4.3 Egypt Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
11.4.4 Algeria Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
11.4.5 Morocco Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 12 Oceania Ankylosing Spondylitis Drug Market Analysis
12.1 Oceania Ankylosing Spondylitis Drug Consumption and Value Analysis
12.2 Oceania Ankylosing Spondylitis Drug Consumption Volume by Types
12.3 Oceania Ankylosing Spondylitis Drug Consumption Structure by Application
12.4 Oceania Ankylosing Spondylitis Drug Consumption by Top Countries
12.4.1 Australia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
12.4.2 New Zealand Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 13 South America Ankylosing Spondylitis Drug Market Analysis
13.1 South America Ankylosing Spondylitis Drug Consumption and Value Analysis
13.1.1 South America Ankylosing Spondylitis Drug Market Under COVID-19
13.2 South America Ankylosing Spondylitis Drug Consumption Volume by Types
13.3 South America Ankylosing Spondylitis Drug Consumption Structure by Application
13.4 South America Ankylosing Spondylitis Drug Consumption Volume by Major Countries
13.4.1 Brazil Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.2 Argentina Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.3 Columbia Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.4 Chile Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.5 Venezuela Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.6 Peru Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.7 Puerto Rico Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
13.4.8 Ecuador Ankylosing Spondylitis Drug Consumption Volume from 2017 to 2022
Chapter 14 Company Profiles and Key Figures in Ankylosing Spondylitis Drug Business
14.1 Amgen
14.1.1 Amgen Company Profile
14.1.2 Amgen Ankylosing Spondylitis Drug Product Specification
14.1.3 Amgen Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.2 Wyeth
14.2.1 Wyeth Company Profile
14.2.2 Wyeth Ankylosing Spondylitis Drug Product Specification
14.2.3 Wyeth Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.3 Takeda
14.3.1 Takeda Company Profile
14.3.2 Takeda Ankylosing Spondylitis Drug Product Specification
14.3.3 Takeda Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.4 Centocor
14.4.1 Centocor Company Profile
14.4.2 Centocor Ankylosing Spondylitis Drug Product Specification
14.4.3 Centocor Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.5 Schering-Plough
14.5.1 Schering-Plough Company Profile
14.5.2 Schering-Plough Ankylosing Spondylitis Drug Product Specification
14.5.3 Schering-Plough Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.6 Mitsubishi Tanabe
14.6.1 Mitsubishi Tanabe Company Profile
14.6.2 Mitsubishi Tanabe Ankylosing Spondylitis Drug Product Specification
14.6.3 Mitsubishi Tanabe Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.7 Abbott
14.7.1 Abbott Company Profile
14.7.2 Abbott Ankylosing Spondylitis Drug Product Specification
14.7.3 Abbott Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.8 Eisai
14.8.1 Eisai Company Profile
14.8.2 Eisai Ankylosing Spondylitis Drug Product Specification
14.8.3 Eisai Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.9 Pfizer
14.9.1 Pfizer Company Profile
14.9.2 Pfizer Ankylosing Spondylitis Drug Product Specification
14.9.3 Pfizer Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
14.10 Johnson & Johnson
14.10.1 Johnson & Johnson Company Profile
14.10.2 Johnson & Johnson Ankylosing Spondylitis Drug Product Specification
14.10.3 Johnson & Johnson Ankylosing Spondylitis Drug Production Capacity, Revenue, Price and Gross Margin (2017-2022)
Chapter 15 Global Ankylosing Spondylitis Drug Market Forecast (2023-2030)
15.1 Global Ankylosing Spondylitis Drug Consumption Volume, Revenue and Price Forecast (2023-2030)
15.1.1 Global Ankylosing Spondylitis Drug Consumption Volume and Growth Rate Forecast (2023-2030)
15.1.2 Global Ankylosing Spondylitis Drug Value and Growth Rate Forecast (2023-2030)
15.2 Global Ankylosing Spondylitis Drug Consumption Volume, Value and Growth Rate Forecast by Region (2023-2030)
15.2.1 Global Ankylosing Spondylitis Drug Consumption Volume and Growth Rate Forecast by Regions (2023-2030)
15.2.2 Global Ankylosing Spondylitis Drug Value and Growth Rate Forecast by Regions (2023-2030)
15.2.3 North America Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.4 East Asia Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.5 Europe Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.6 South Asia Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.7 Southeast Asia Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.8 Middle East Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.9 Africa Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.10 Oceania Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.2.11 South America Ankylosing Spondylitis Drug Consumption Volume, Revenue and Growth Rate Forecast (2023-2030)
15.3 Global Ankylosing Spondylitis Drug Consumption Volume, Revenue and Price Forecast by Type (2023-2030)
15.3.1 Global Ankylosing Spondylitis Drug Consumption Forecast by Type (2023-2030)
15.3.2 Global Ankylosing Spondylitis Drug Revenue Forecast by Type (2023-2030)
15.3.3 Global Ankylosing Spondylitis Drug Price Forecast by Type (2023-2030)
15.4 Global Ankylosing Spondylitis Drug Consumption Volume Forecast by Application (2023-2030)
15.5 Ankylosing Spondylitis Drug Market Forecast Under COVID-19
Chapter 16 Conclusions
Research Methodology